{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:57:14Z","timestamp":1782953834086,"version":"3.54.5"},"reference-count":24,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: For stage IIIb\u2013IV ovarian cancer, bevacizumab-containing treatment is considered the standard of care. The purpose of this study was to evaluate the efficacy of bevacizumab in combination with carboplatin and paclitaxel as a first-line treatment for advanced ovarian cancer. Materials and Methods: Eligible patients had stage IIIc\u2013IV ovarian cancer according to the International Federation of Gynecology and Obstetrics with no clinical signs or symptoms of gastrointestinal obstruction or a history of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess or evidence of rectosigmoid involvement by pelvic examination, bowel involvement on computed tomography, or clinical symptoms of bowel obstruction in the previous 6 months. After debulking surgery, the patients received 175 mg\/m2 paclitaxel and carboplatin (AUC 6) for the first six cycles and 7.5 mg\/kg bevacizumab every three weeks up to 17 cycles until disease progression, unacceptable toxicity, or consent withdrawal. The primary endpoint was progression-free survival. The secondary endpoint was overall survival. Results: Between April 2017 and March 2020, 35 patients began study treatment. Bevacizumab was administered at 7.5 mg\/kg in all the patients and for more than 7.5 months in 70% of them. The median progression-free survival was 20 months (95% CI: 16\u201323). The median overall survival was not reached. Conclusions: This was, to our knowledge, the first trial in Serbia to show progression-free survival and overall survival of combination regimens in advanced ovarian cancer. Based on the observed progression-free survival, bevacizumab combined with chemotherapy should be considered as a standard option in advanced ovarian cancer.<\/jats:p>","DOI":"10.3390\/medicina58050607","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T22:20:20Z","timestamp":1651098020000},"page":"607","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bevacizumab with Chemotherapy as a First-Line Treatment for Advanced Ovarian Cancer in a Serbian Cohort"],"prefix":"10.3390","volume":"58","author":[{"given":"Irena","family":"Conic","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"},{"name":"Oncology Clinic, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-7128","authenticated-orcid":false,"given":"Bojan","family":"Nedovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-9720","authenticated-orcid":false,"given":"Slavica","family":"Stojnev","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"},{"name":"Center for Pathology, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinka","family":"Todorovska","sequence":"additional","affiliation":[{"name":"Oncology Clinic, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Dimitrijevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"},{"name":"Oncology Clinic, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-3450","authenticated-orcid":false,"given":"Miljan","family":"Krstic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"},{"name":"Center for Pathology, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Djordjevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"},{"name":"Center for Pathology, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Djordjevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nis, 18000 Nis, Serbia"},{"name":"Center for Pathology, Clinical Center Nis, 18000 Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","article-title":"Ovarian cancer relapse: From the latest scientific evidence to the best practice","volume":"140","author":"Luvero","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2021.01.028","article-title":"The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis","volume":"161","author":"Liu","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Scully, R.E., Scully, R., Sobin, L., and Serov, S. (1999). Histological Typing of Ovarian Tumours, Springer Science & Business Media.","DOI":"10.1007\/978-3-642-58564-7"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.10.019","article-title":"The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)","volume":"144","author":"Matz","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/01.ogx.0000452705.82050.e4","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"69","author":"Hilpert","year":"2014","journal-title":"Obstet. Gynecol. Surv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","article-title":"Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA single-arm phase 3B study","volume":"27","author":"Oza","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14737140.2017.1398088","article-title":"Optimizing treatment in recurrent epithelial ovarian cancer","volume":"17","author":"Corrado","year":"2017","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_17","first-page":"1057","article-title":"Sustained effect of continuous treatment with bevacizumab following bevacizumab in combination with chemotherapy in a human ovarian clear cell carcinoma xenograft model","volume":"42","author":"Ishikura","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdv012","article-title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial","volume":"26","author":"Masi","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_19","first-page":"173","article-title":"Prognostic factors for the efficacy of bevacizumab beyond progression in metastatic colorectal cancer","volume":"12","author":"Bochis","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yamamoto, S., Nagashima, K., Kawakami, T., Mitani, S., Komoda, M., Tsuji, Y., Izawa, N., Kawakami, K., Yamamoto, Y., and Makiyama, A. (2021). Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08890-6"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2019.02.008","article-title":"Phase III trials in ovarian cancer: The evolving landscape of front line therapy","volume":"153","author":"Naumann","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Harter, P., Bidzin\u00b4ski, M., Colombo, N., Floquet, A., Rubio Perez, M.J., Kim, J.W., Lheureux, S., Marth, C., Nyvang, G.B., and Okamoto, A. (2019). DUO-O: A randomized phase III trial of durvalumab (durva) in combination with chemotherapy and bevacizumab (bev), followed by maintenance durva, bev and olaparib (olap), in newly diagnosed advanced ovarian cancer patients. J. Clin. Oncol., 37.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5598"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2021.02.002","article-title":"REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer","volume":"161","author":"Sjoquist","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.16601","article-title":"Bevacizumab and gastrointestinal perforations: A review from the FDA Adverse Event Reporting System (FAERS) database","volume":"54","author":"Wichelmann","year":"2021","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/5\/607\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:02:21Z","timestamp":1760137341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/58\/5\/607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["medicina58050607"],"URL":"https:\/\/doi.org\/10.3390\/medicina58050607","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}